Last updated: April 25, 2026
What is the case and what claims were at issue?
RECKITT BENCKISER LLC sued AMNEAL PHARMACEUTICALS LLC in the U.S. District Court under case number 1:15-cv-02155. The action centers on patent protection tied to a marketed consumer-health product and the generic entry posture taken by Amneal. The litigation posture is consistent with the Hatch-Waxman framework: a branded manufacturer asserts infringement of one or more listed patents against a proposed generic, typically following an ANDA filing and patent-certification disputes.
Where was the case filed and how did the docket progress?
The matter is docketed as 1:15-cv-02155 (filed in 2015). The docket is driven by:
- Complaint and infringement assertions by Reckitt Benckiser
- Response filings by Amneal
- Case management, claim construction activity, and motions practice typical for Hatch-Waxman patent cases
- Disposition through settlement, dismissal, or a final judgment on infringement/invalidity (the specific outcome requires docket-level facts)
What patents were asserted, and how is infringement typically framed?
The core of Hatch-Waxman patent litigation is infringement under 35 U.S.C. § 271 and contesting validity under defenses such as:
- Lack of novelty (anticipation)
- Obviousness (35 U.S.C. § 103)
- Indefiniteness or lack of enablement under 35 U.S.C. § 112
- Non-infringement based on formulation, dosage form, process, or other claim limitations
In these cases, claim charts usually track:
- Active ingredient identity and chemical form
- Formulation parameters (excipients, ratios, solubility/availability-related features)
- Dosage form architecture (for example, multilayer or release profiles when relevant)
- Manufacturing process steps (when process claims are asserted)
Actionable note for patent strategy: the litigation record generally rewards the party that narrows the case early on claim construction. The winning infringement theory is usually the one that survives the narrowing of key limitations (for branded) or that invalidates the narrowed interpretation (for generic).
What technical claim themes usually decide outcomes in these disputes?
For consumer-health formulations and dosage forms, the decisive claim issues usually cluster into four buckets:
1) Compositions and formulation limitations
- Exact ingredient selection
- Required concentration ranges
- Functional limitations tied to performance (such as dissolution or stability metrics)
2) Dosage form and release behavior
- Whether the accused product structurally matches the claim
- Whether release kinetics or layer configurations map onto claimed features
3) Process limitations
- Only if process claims are asserted: whether Amneal’s manufacturing method matches each step of the asserted claims
- Whether process-related evidence can be obtained and credibly linked to ANDA manufacture
4) “Means-plus-function” or functional language
- Whether the claim is properly construed and supported by the specification
- Whether the generic product meets the function as construed
Actionable note for portfolio enforcement: if the asserted claims include broad functional language, the generic’s invalidity and non-infringement arguments often concentrate on (a) narrowing construction that preserves a novelty boundary or (b) attacking lack of adequate disclosure.
How does the Hatch-Waxman framework shape the litigation incentives?
Hatch-Waxman cases drive deal dynamics even when merits are disputed because:
- A final merits outcome directly affects launch timing
- A settlement often resolves not only liability but also timing of market entry
- Stays and/or timing mechanisms can control economic exposure
Actionable note for licensing and valuation: the economic value of asserted patents often ties less to universal claim coverage and more to whether the patents are enforceable against the specific ANDA design and whether the case posture signals a credible pathway to injunction or a high-probability non-infringement win.
What is the likely procedural posture that matters to investors and litigators?
For a 2015-filed Hatch-Waxman action like this one, the most investment-relevant docket milestones typically include:
- Claim construction order: defines the “game board” for both infringement and invalidity
- Summary judgment motions: narrows or ends issues early
- Pretrial rulings: admissibility and scope of expert testimony
- Settlement or dismissal: converts litigation risk into enforceable commercial terms (if the parties document those terms)
Without the docket’s specific filings listed here, the operative merits details cannot be accurately reconstructed. What can be stated at a business level is that the case would have followed these phases and that the strategic “tipping point” is almost always claim construction plus the expert narrative tied to the accused product.
Litigation risk mapping: what each side is trying to prove
What does Reckitt Benckiser need to win?
- The asserted claims must be construed to cover the ANDA product
- The accused product must meet each claim limitation
- The asserted patents must survive invalidity challenges
What does Amneal need to win?
- A narrower claim construction that eliminates one or more essential limitations
- Invalidity of one or more asserted claims (anticipation/obviousness/§ 112)
- Non-infringement via formulation or structural non-match
What would a strong outcome look like for each side?
- For Reckitt: court orders a finding of infringement (or issues injunctive relief) on at least one asserted claim, with a likely path to preventing or delaying launch.
- For Amneal: court grants summary judgment of non-infringement and/or invalidity on key asserted claims, removing launch barriers.
In practice, most Hatch-Waxman consumer-health cases resolve through settlement when either:
- The branded party’s likelihood of overcoming claim-construction narrowing is mixed, or
- The generic’s invalidity story reduces expected trial risk.
How should a patent analyst treat the likely commercial endpoint (settlement vs. judgment)?
For corporate decision-making, the endpoint matters more than the intermediate procedural steps:
- Settlement agreement: drives revenue protection and launch timing, sometimes with licensing and payment terms
- Judgment: can set precedent for claim interpretation and future enforcement against other applicants
Because the requested input includes only the caption and docket number, the case outcome is not reproducible here without specific docket dispositions.
Key Takeaways
- 1:15-cv-02155 is a Hatch-Waxman-style dispute in which Reckitt Benckiser asserted infringement claims against Amneal’s proposed generic pathway.
- The decisive merits hinge on claim construction and whether the accused ANDA product meets every limitation of the asserted claims.
- For investors and litigators, the most value-dense docket items are typically claim construction, expert testimony alignment, summary judgment rulings, and the case resolution mechanism (judgment vs. settlement).
FAQs
What court handled 1:15-cv-02155?
It is docketed as 1:15-cv-02155 in U.S. federal district court, with the case caption naming RECKITT BENCKISER LLC as plaintiff and AMNEAL PHARMACEUTICALS LLC as defendant.
What legal theory governs the suit?
The suit follows the standard patent-infringement framework used in Hatch-Waxman disputes: infringement under 35 U.S.C. § 271 tied to a generic market entry challenge to listed patents.
What issues usually decide Hatch-Waxman formulation/dosage cases?
They usually turn on claim construction (what the claims mean) and product mapping (whether the accused generic matches each claim limitation).
What is the biggest strategic lever in this type of litigation?
Early narrowing of disputed claim terms through claim construction and alignment of expert evidence to the narrowed limitations.
Does outcome typically come from trial or settlement?
In this category of cases, resolution often comes through settlement or other negotiated resolution, but the docket disposition determines the actual outcome.
References
[1] RECKITT BENCKISER LLC v. AMNEAL PHARMACEUTICALS LLC, No. 1:15-cv-02155 (Docket/Court case record).
